Sign up for the QMED & MD+DI Daily newsletter.
Deal Could Enhance Cancer Diagnostics
Fujirebio Diagnostics, Inc. (Exton, PA), a leader in cancer diagnostics, announced it has bought rival CanAg Diagnostics AB (Gothenburg, Sweden). Both companies are known for their serum tumor markers. Combining the R&D efforts of both firms could enhance the development of new cancer assays, which are always needed.
June 1, 2006
1 Min Read
.svg?width=1280&auto=webp&quality=95&format=jpg&disable=upscale "MDDI")
Fujirebio Diagnostics, Inc. (Exton, PA), a leader in cancer diagnostics, announced it has bought rival CanAg Diagnostics AB (Gothenburg, Sweden). Both companies are known for their serum tumor markers. Combining the R&D efforts of both firms could enhance the development of new cancer assays, which are always needed.
You May Also Like
.png?width=300&auto=webp&quality=80&disable=upscale)
.png?width=300&auto=webp&quality=80&disable=upscale)
.png?width=300&auto=webp&quality=80&disable=upscale)